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PEPTIDE 204-212 of lipocortin (LC) 5 inhibited porcine
pancreatic phospholipase A (PLA2) induced rat stomach
strip contractions and ADP induced rabbit platelet ag-
gregation in a concentration dependent manner (IC30 of
10 #M and 400 ktM, respectively). The first two amino acids
are not necessary since the eptapeptide 206-212 was equi-
potent in both assays (IC30 of 12.5/tM and 420 M). Of the
two pentapeptides 204-208 and 208-212 only the latter
showed inhibitory activity in both models although the
potency was much reduced (IC30 of 170 #M and 630/tM)
compared with that of the parent nonapeptide. Compar-
ison of peptide 204-212 effects with those of its analogues
on LC1 and LC2 indicate that lysine 208 and aspartic acid
211 are essential in order to maintain a fully active non-
apeptide.
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Introduction
The term lipocortin (LC) indicates the members
of a family of calcium- and phospholipid-binding
proteins, also called annexins, whose physiological
role remains to be fully clarified. They have been
proposed to mediate part of the anti-inflammatory
action of glucocorticoid hormones, and to date
clear anti-inflammatory activity has been described
for three members of this family, LC1,
2 LC23 and
LC5. 4
It has been suggested recently that the
anti-inflammatory site of human LC1 may be
located in region 247-255 which is strictly
homologous to portion 39-47 of rabbit uter-
oglobin, another steroid-inducible anti-PLA2 pro-
tein. The nonapeptides corresponding to these
high homology regions showed anti-inflammatory
activity, and have been named antiflammins (AFs),
with AF-1 (Met-Gln-Met-Lys-Lys-Val-Leu-Asp-
Ser) being drawn from uteroglobin and AF-2
(His- Asp- Met-Asn- Lys- Val- Leu-Asp- Leu) from
LC1. A subsequent study comparing the amino acid
sequences of uteroglobin and human LC5 has also
determined a high homology between AF-1 and the
region 204-212 of LC5.
6 This nonapeptide inhibits
PLA2 dependent processes in vitro such as release of
prostaglandin E2 from stimulated macrophages or
fibroblasts. In vivo, the LC5 derived peptide has been
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demonstrated to be anti-inflammatory reducing the
oedema caused by the injection of carrageenin into
rat paw.
6 In a recent investigation the pharmaco-
logical activity of this nonapeptide has been
confirmed in another experimental system, i.e. the
release of prostacyclin from aorta rings.
7 In this
model the inhibition exerted by peptide 204-212
(ICs0 around 10#g/ml) disappeared when ar-
achidonic acid was added to the incubation
medium.
However, few studies have investigated the
structural requirements of the AFs which may be
responsible for the biological activity of these
peptides. One report has shown that AFs shorter
than nine amino acids lose their in vitro anti-PEA2
activity, Another study has shown the four amino
acid core sequence (Lys-Val-Leu-Asp) to demon-
strate activity by reducing ADP induced platelet
aggregation in vitro. More recently it has been
shown that replacement of methionine with alanine
or norleucine at amino acid position 3 of the AFs
can be achieved without loss of activity. This study
has also pointed out that leucine and serine are
interchangeable on position 9.
In the present work the efficacy of a number of
fragments derived from peptide 204-212 of LC5 as
well as two peptides from corresponding portions
of LC1 and LC2 (hereafter referred to as analogues)
have been evaluated in two in vitro models: ADP
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induced rabbit washed platelet aggregation and
PLA2 induced rat stomach strip contractions.
6
Based on the data obtained some structural
requirements of peptide 204-212 of LC5 and,
possibly, of other AFs are discussed.
Materials and Methods
Peptides" Peptides were purchased from Protein &
Peptide Research (Reading, UK). Purity was always
more than 95% as assessed by HPLC analysis. The
correct amino acid composition and molecular
weight were checked by mass spectrometry (all data
furnished by the manufacturer). The peptides used
throughout this study are reported in Table 1.
ADP induced aggregation of rabit washed platelets: Male
New Zealand rabbits (2.5-3.0 kg body weight) were
bled by the aorta and the blood collected in 3.15%
sodium citrate. Washed platelets, obtained as
described,
1 were suspended at the concentration of
5 107 in 0.45 ml of Tyrode’s buffer containing
3 mg/ml of bovine serum albumin. After warming
at 37C, 50 #1 of sample, 10 #1 ofADP (1 mM; final
concentration 2 x 10-SM) and 5/1 of GaG12
(100mM) were added simultaneously and ag-
gregation recorded by using a Chronolog Dual
Aggregometer (Chronolog Corporation, Haver-
town, PA, USA). Data are reported as the
percentage of control aggregation measured when
50/1 of buffer were used instead of the sample.
PLAe induced rat stomach strip contractions: Isolated
stomach strip preparations were prepared from
male Wistar rats (250-300 g body weight) and
contractions were elicited by incubation of the
tissue with porcine pancreatic PLA2 as described
previously. In these experimental conditions
incubation with indomethacin (2/g/ml) reduced by
80% the contractile response evoked by PLA2,
suggesting that the greater majority of the
contraction recorded was due to arachidonic acid
release. Stomach strip preparations were suspended
under 2.5 g load in 20ml organ chambers and
Table 1. Peptides used in this study
Region Protein
Amino acid sequence
2 3 4 5 6 7 8 9
204-212 LC5
Fragments
206-212 LC5
208-212 LC5
204-208 LC5
Analogues
231-239 LC1
223-231 LC2
Ser- H is- Leu-Arg- Lys-Val- Phe-Asp- Lys
Leu Arg- Lys-Val- Phe-Asp- Lys
Lys-Val- Phe-Asp- Lys
Ser- His- Leu-Arg- Lys
Pro-G In- Leu Arg-Arg-Val- Phe-G In- Lys
Pro-H is- Leu-G In- Lys-Val- Phe-Asp-Arg
LC" lipocortin.
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bathed with gassed (95% 02; 5% CO2) Krebs’
solution maintained at 37C. Tissue contractions
were recorded via isotonic transducers (type 7006,
Basile, Comerio, Italy) coupled to a dual channel
recorder (type 7070, Basile). Preparations were
equilibrated for a minimum of 1 h before starting
any experimental procedure. To contract tissue,
4.4 #g/ml of porcine pancreatic PLA2 was added to
the bathing solution. This concentration has been
reported previously to cause approximately 85% of
maximum contraction. In all cases, at least two
consecutive contractions of similar magnitude were
obtained to this concentration of PLA2 before
allowing evaluation of the peptides. Peptides were
incubated with the isolated tissue for 30 min, after
which the preparations were again challenged with
the same concentration of agonist.
6 To standardize
the contractions obtained from different tissue
preparations, responses are expressed as a percent-
age of the contraction elicited by PLA2 prior to
incubation with the test peptides.
Materials: Chemicals were purchased from Sigma
Chemical Co. (Milan, Italy) while salts of analytical
grade were obtained from Merck (Darmstaad,
Germany).
Results
Effect ofpeptide 204-212 ofLC5 and itsfragments: Figure
1A shows the inhibition exerted by the various
peptides on rat stomach strip contractions elicited
by PLA2. The maximal inhibition observed was
60-65%. For peptide 204-212 an IC30 of 10/M
could be measured. The seven amino acid fragment
206-212 was similarly active (IC30 12.5/M). Of
the two pentapeptides only peptide 208-212
retained some inhibitory activity (IC0 170/M)
while the fragment 204-208 was inactive. A similar
pattern of effects was observed on ADP induced
aggregation although higher concentrations of
peptides were required to obtain a significant
inhibition (Fig. 2A). Peptide 206-212 caused almost
maximal inhibitory effect, although in terms of IC30
(420/M) it was equiactive with the parent
nonapeptide (400/M). However, in this model
both pentapeptides were active with an IC0 of
630 #M for peptide 208-212 and of 890/M for
peptide 204-208.
Effect of the analogues of peptide 204-212 of LC5: When
the region 204-212 of LC5 is analysed on LC1 and
LC2, following the alignment described by
Pepinsky et al.,11 tWO other nonapeptides can be
identified (reported in Table 1). The analogue of
LC2 was as active as peptide 204-212 of LC5, with
an IC0 of 4/M in the smooth muscle model (Fig.
1B) and of 420/zM in the platelet aggregation
system (Fig. 2B). The analogue of LC1 was lessThe sequence ofpeptide 204-212 of lipocortin 5
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FIG. 1. Effect of peptide 204-212 of lipocortin 5 (LC5) on PLA2 induced
rat stomach strip contractions in comparison with the efficacy of its
fragments (panel A) and analogues from lipocortin and 2 (LC1, LC2)
(panel B). Values are mean 4- S.E.M. of 4-9 separate determinations.
Values _<80% of control contractions (induced with PLA2 4.4/g/ml) are
statistically significant (p < 0.05, paired Student’s test on original
values). Key: (C), 204-212 LC5; O, 206-212 LC5; [], 208-212 LC5’
Fq, 204-208 LC5 /% 231-239 LCI" A, 223-231 LC2.
active in both models, with an IC30 of 45 #M on
stomach strip contractions (Fig. 1B) and an
approximate IC30 of 1 mM on platelet aggregation
(Fig. 2B). In the latter case inhibition of platelet
aggregation did not actually reach 30% with any
concentration used.
Discussion
The present study has investigated the biological
activity of nonapeptide 204-212 of LC5 and that of
related fragments and analogues. For this purpose
two in vitro experimental models already reported
to be affected by AFs, have been used. The first
system was the PLA2 elicited rat stomach strip
contractions.
6 In this model PLA2 induced
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FIG. 2. Effect of peptide 204-212 of lipocortin 5 (LC5) on ADP induced
rabbit platelet aggregation in comparison with the activity of its fragments
(panel A) and analogues of lipocortin and 2 (LC1, LC2) (panel B).
Values are mean 4-S.E.M. of 3-10 separate determinations. Values <70%
of control aggregation (induced by ADP 2 x 10-5 M) reach the statistical
significance (p < 0.005, paired Student’s test performed on original
values). Key as in Fig. 1.
contractions are proposed to be due mainly
to prostaglandin formation inasmuch as in-
domethacin exerts profound inhibition (79.1%) of
this response.
6 Interestingly, 2h incubation of
stomach strips with dexamethasone resulted in a
potent inhibition (62.4%) of the contractions
evoked by the stimulus, this effect disappearing in
the presence of cycloheximide.
6 This may indicate
the involvement of an endogenous LC in the action
of the steroid. This observation is substantiated by
the fact that human recombinant LC5 inhibits this
PLA2 contractile activity (K.G. Mugridge, un-
published data). Peptide 204-212 of LC5 inhibited
PLA2 induced contractions in a concentration
dependent manner, the effect being selective since
it did not affect to any extent the contractile activity
elicited by either arachidonic acid or prostaglandin
E2 .6 AF-2 was found to be as active as peptide
204-212.
6 The second model used in this study was
the ADP induced platelet aggregation which has
been reported to be sensitive to both AF-1 and
AF-2.
8 Their effectiveness has been related to
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inhibition of endogenous PLA2 activity, inasmuch
as a loss of effect was observed in the presence of
arachidonic acid.
8 Similarly, a recent study has
shown peptide 204-212 of LC5 to inhibit the
spontaneous release of prostacyclin from isolated
rat aorta rings but not arachidonic acid-stimulated
release.:
In both experimental systems, peptide 204-212
exerted a concentration dependent inhibition
although different levels of sensitivity were found
between the two models. The reason for the lower
sensitivity observed in the platelet model is not
clear. Washed platelets were used in these
experiments to eliminate plasma proteases and
therefore the likelihood of an aggressive breakdown
of the peptides. However, similar high concentra-
tions of AFs have been used in the same model.
The seven amino acid fragment 206-212 fully
retained the inhibitory activity of the parent
nonapeptide. This eptapeptide was also equipotent
to 204-212 in inhibiting the release of prostaglandin
E2 from rat peritoneal macrophages stimulated with
opsonized zymosan.
6 Taken together, these findings
indicate that the first two amino acids of the
nonapeptide 204-212 are not necessary to achieve
biological activity. The pentapetide 208-212 was
active in both systems, albeit with lower potency
than the parent nonapeptide. Contrastingly, frag-
ment 204-208 was inactive on PLA2 induced
contractions, but exhibited some activity in the less
sensitive platelet aggregation model. This effect in
the latter model may be related to different
mechanism(s). Recently, peptide 204--209 of LC5
has been proposed to represent the sequence
responsible for the anticoagulant action, this effect
disappearing when histidine 205 is substituted. 12’13
Compared to AF-2, region 204-212 of the third
repeat of LC5 is well conserved in the other
members of the LC family, not only in terms of
primary structure11 but also from a three
dimensional point of view.4 The nonapeptide
231-239 of LC1 and the nonapeptide 223-231 of
LC2 have more than 50% identity with peptide
204-212 of LC5. They have also a good homology
sequence with AF-2. These observations prompted
us to evaluate the et:fect of these analogues.
Moreover, taking into account the concept that the
first two amino acids of peptide 204-212 are not
important to the achievement of the biological
activity, the effectiveness of peptide 204-212 and
these analogues in relation to the seven amino acid
sequence was compared. Indeed, as highlighted in
Table 2, peptide 223-231 of LC2 was equiactive to
the LC5 derived nonapeptide, this indicating that
the fourth and the last amino acids (207 and 212 on
peptide 204-212 of LC5) are probably not
important. On the contrary, the fragment 231-239
of LC1, differing only in the fifth and eighth amino
acid, was at least four-to-five-fold less active than
peptide 204-212. This indicates that lysine 208
(position 5 of peptide 204-212) and aspartic acid
211 (position 8) must be present in order to
maintain full effectiveness. This fact is reinforced
by the presence of these two amino acids, in the
same position and spaced by two hydrophobic
residues, in both AF-1 and AF-2. The possibility
also that valine 209 (position 6) and phenylalanine
210 (position 7) may have a role in the achievement
of the full activity cannot be completely ruled out
from these data, although AF-2 has leucine in
position 7. Leucine 203 (position 3) is different in
AF sequences where there is a methionine.
Moreover, in this position alanine or norleucine
also may be present without loss of activity.
9
In summary, in this study some of the possible
structural requirements for the LC5 derived
nonapeptide using two in vitro models were
investigated. The data obtained indicate that
biological activity, fully retained by the seven amino
acid fragment, is due to the core region 208-212
where lysine 208 and aspartic acid 211 may play a
pivotal role. Since the anti-inflammatory activity
originally ascribed to these peptidess’6 has now been
confirmed7,s and extended,<7 definition of the key
amino acids required for biological activity may
serve for designing non-peptidergic molecules
endowed with this inhibitory effect on the acute
inflammatory process.
Table 2. Comparison between peptide 204-212 of LC5 and its analogues
Amino acid sequence IC3o
Region Protein 2 3 4 5 6 7 8 9 RSS WP
204-212 LC5 Ser-H is- Leu-Arg- Lys-Val- Phe-Asp- Lys
231-239 LC1 Pro GIn Arg Gin,
223-231 LC2 Pro Gin Arg
1.00 1.00
4.50 2.50
0.40 1.05
Indicates identity with the top peptide sequence. LC, lipocortin; RSS, rat stomach strip model;
WP, washed platelet aggregation. IC3o values have been compared by taking as 1.00 those of
LC5 peptide (10/M and 400/M for RSS and WP, respectively).
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